$IRD

2020 Q4 Form 10-K Financial Statement

#000114036121008099 Filed on March 11, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 2019 Q4
Revenue -$1.150M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin -$1.910M $2.820M $1.550M
YoY Change -223.23% -50.79% -30.8%
% of Gross Profit
Research & Development $8.376M $6.648M $450.0K
YoY Change 1761.33% 21.39% -83.52%
% of Gross Profit
Depreciation & Amortization -$20.00K $8.000K $10.00K
YoY Change -300.0% 166.67% 0.0%
% of Gross Profit
Operating Expenses $8.376M $19.97M $2.010M
YoY Change 316.72% 376.22% -59.53%
Operating Profit -$19.97M
YoY Change 376.22%
Interest Expense -$8.250M $6.847M $140.0K
YoY Change -5992.86% 385.95% -92.43%
% of Operating Profit
Other Income/Expense, Net $9.000K
YoY Change -113.24%
Pretax Income -$20.12M -$24.62M -$1.870M
YoY Change 975.94% 299.09% -40.06%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.12M -$24.62M -$1.870M
YoY Change 975.94% 299.09% -40.0%
Net Earnings / Revenue
Basic Earnings Per Share -$5.28
Diluted Earnings Per Share -$1.283M -$5.28 -$1.870M
COMMON SHARES
Basic Shares Outstanding 4.661M 4.019M
Diluted Shares Outstanding 4.661M

Balance Sheet

Concept 2020 Q4 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.40M $16.40M $12.22M
YoY Change 34.21% 34.21% -17.04%
Cash & Equivalents $16.40M $16.40M $1.537M
Short-Term Investments $3.000M
Other Short-Term Assets $26.00K $1.270M $5.000K
YoY Change 420.0% 182.22% -99.1%
Inventory
Prepaid Expenses $1.243M $19.00K
Receivables $0.00
Other Receivables
Total Short-Term Assets $17.67M $17.67M $1.762M
YoY Change 902.72% 39.57% -88.92%
LONG-TERM ASSETS
Property, Plant & Equipment $14.00K $10.00K $22.00K
YoY Change -36.36% -96.43% -80.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $30.00K
YoY Change 0.0%
Other Assets
YoY Change
Total Long-Term Assets $14.00K $10.00K $22.00K
YoY Change -36.36% -96.77% -84.64%
TOTAL ASSETS
Total Short-Term Assets $17.67M $17.67M $1.762M
Total Long-Term Assets $14.00K $10.00K $22.00K
Total Assets $17.68M $17.68M $1.784M
YoY Change 891.14% 36.31% -88.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.214M $1.210M $342.0K
YoY Change 254.97% 146.94% -37.82%
Accrued Expenses $1.971M $1.970M $621.0K
YoY Change 217.39% 114.13% -76.21%
Deferred Revenue $1.500M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.185M $3.190M $9.344M
YoY Change -65.91% 9.62% 196.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.96M $27.96M $110.0K
YoY Change 25318.18% 25318.18% -95.28%
Total Long-Term Liabilities $27.96M $27.96M $110.0K
YoY Change 25318.18% 25318.18% -95.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.185M $3.190M $9.344M
Total Long-Term Liabilities $27.96M $27.96M $110.0K
Total Liabilities $31.15M $31.15M $9.344M
YoY Change 233.36% 934.88% 70.51%
SHAREHOLDERS EQUITY
Retained Earnings -$32.68M -$8.055M
YoY Change 305.65% -94.79%
Common Stock $1.000K $173.3M
YoY Change -100.0% 4.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.47M -$13.47M -$7.560M
YoY Change
Total Liabilities & Shareholders Equity $17.68M $17.68M $1.784M
YoY Change 891.14% 36.31% -88.88%

Cashflow Statement

Concept 2020 Q4 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$20.12M -$24.62M -$1.870M
YoY Change 975.94% 299.09% -40.0%
Depreciation, Depletion And Amortization -$20.00K $8.000K $10.00K
YoY Change -300.0% 166.67% 0.0%
Cash From Operating Activities -$2.660M -$6.797M -$1.720M
YoY Change 54.65% 89.17% -62.77%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$2.460M $540.0K $3.000M
YoY Change -182.0% -82.69% 50.0%
Cash From Investing Activities -$2.460M $539.0K $3.000M
YoY Change -182.0% -2256.0% 50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.12M 21.12M 0.000
YoY Change 348.98% -100.0%
NET CHANGE
Cash From Operating Activities -2.660M -6.797M -1.720M
Cash From Investing Activities -2.460M 539.0K 3.000M
Cash From Financing Activities 21.12M 21.12M 0.000
Net Change In Cash 16.00M 14.86M 1.280M
YoY Change 1150.0% 1268.51% -69.16%
FREE CASH FLOW
Cash From Operating Activities -$2.660M -$6.797M -$1.720M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$2.660M -$6.797M -$1.720M
YoY Change 54.65% 87.87% -62.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1214000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
342000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1971000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
621000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
262000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
186000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
495000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19207000
CY2020 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
64000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
308000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1506000
CY2020 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
971000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1080000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
308000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1506000
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1014000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
873000
CY2020Q4 us-gaap Assets
Assets
17682000
CY2019Q4 us-gaap Assets
Assets
1784000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1762000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
17668000
CY2020Q4 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
10458000
CY2020Q4 us-gaap Business Acquisition Share Price
BusinessAcquisitionSharePrice
7.24
CY2020Q4 us-gaap Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
1120800
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
14862000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1086000
CY2020 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
2014000
CY2019 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2020Q4 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
2014000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1537000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
451000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16399000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
16399000
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1537000
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
16100000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2852485
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10882495
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2852485
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10882495
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6169000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24620000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-style: italic; font-weight: bold;">Concentration of Credit Risk</div><div>&#160;</div><div style="text-align: justify;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company&#8217;s cash is held by one large, long-standing financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of December 31, 2020, the Company had deposits that exceeded federally insured amounts by $16.1 million.</div></div>
CY2019 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
125000
CY2020 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2019 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1910000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
831000
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0
CY2019Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4977000
CY2019 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2020 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
100000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
0
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
547000
CY2019Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
76000
CY2020Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
0
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1859000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4647000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
0
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
300000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
454000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
1000000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
2700000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3351000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1228000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
600000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
200000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
9000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
8000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
87000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
0
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4647000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1859000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
466000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
81000
CY2019 us-gaap Depreciation
Depreciation
3000
CY2020 us-gaap Depreciation
Depreciation
8000
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2714000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.28
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.17
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.011
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.138
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.242
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
350000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
320000
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2019 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-499000
CY2020 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1486000
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3672000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1820000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2818000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24620000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6169000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
467000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1260000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
792000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-168000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-58000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
906000
CY2019 us-gaap Interest Expense
InterestExpense
1409000
CY2020 us-gaap Interest Expense
InterestExpense
6847000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P7M
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
20000
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
54000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1784000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17682000
CY2020Q4 us-gaap Liabilities
Liabilities
31149000
CY2019Q4 us-gaap Liabilities
Liabilities
9344000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3185000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9344000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6797000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3593000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-24620000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-6169000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
539000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4704000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21120000
CY2020 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
68000
CY2019 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
0
CY2020 us-gaap Noncash Or Part Noncash Acquisition Other Liabilities Assumed1
NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
0
CY2019 us-gaap Noncash Or Part Noncash Acquisition Other Liabilities Assumed1
NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
76000
CY2019 us-gaap Notes Assumed1
NotesAssumed1
0
CY2020 us-gaap Notes Assumed1
NotesAssumed1
9365000
CY2019Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
75000
CY2020Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
0
CY2020Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
1300000
CY2019Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
690000
CY2020Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0
CY2019Q4 us-gaap Notes Receivable Related Parties Current
NotesReceivableRelatedPartiesCurrent
50000
CY2020Q4 us-gaap Notes Receivable Related Parties Current
NotesReceivableRelatedPartiesCurrent
0
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Operating Expenses
OperatingExpenses
19968000
CY2019 us-gaap Operating Expenses
OperatingExpenses
4193000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Next Rolling Twelve Months
OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths
36000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-19968000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-4193000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
26000
CY2019 us-gaap Other Noncash Expense
OtherNoncashExpense
252000
CY2020 us-gaap Other Noncash Expense
OtherNoncashExpense
492000
CY2019 us-gaap Other Payments To Acquire Businesses
OtherPaymentsToAcquireBusinesses
0
CY2020 us-gaap Other Payments To Acquire Businesses
OtherPaymentsToAcquireBusinesses
1475000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-68000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
25000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9000
CY2020 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
506000
CY2019 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0
CY2020Q4 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1575000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1769000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
10000
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
625000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1243000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
19000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
149000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1269000
CY2020 us-gaap Proceeds From Hedge Financing Activities
ProceedsFromHedgeFinancingActivities
21150000
CY2019 us-gaap Proceeds From Hedge Financing Activities
ProceedsFromHedgeFinancingActivities
0
CY2019 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4383000
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2197000
CY2020 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2019 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
323000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
58000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22000
CY2020 us-gaap Recapitalization Costs
RecapitalizationCosts
689000
CY2019 us-gaap Recapitalization Costs
RecapitalizationCosts
0
CY2019 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
10502000
CY2020Q4 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
8376000
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2373000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6648000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8055000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32675000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2126000
CY2019 us-gaap Stock Issued1
StockIssued1
0
CY2020Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7091878
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
8115000
CY2020Q4 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
8115000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
308000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1506000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.33
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.65
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
6953000
CY2020 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0
CY2020 us-gaap Stock Issued1
StockIssued1
8883000
CY2020 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.0565
CY2020Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.0565
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-13467000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-7560000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1699000
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-style: italic; font-weight: bold;">Use of Estimates</div><div>&#160;</div><div style="text-align: justify;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div></div>
CY2019Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
27964000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2844832
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4661110
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q2 dei Entity Public Float
EntityPublicFloat
11392767
CY2020 dei Entity Registrant Name
EntityRegistrantName
Ocuphire Pharma, Inc.
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001228627
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10929881
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 ocup Fair Value Of Warrants And Options Issued To Affect Merger
FairValueOfWarrantsAndOptionsIssuedToAffectMerger
768000
CY2019Q4 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
0
CY2020Q4 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
1440000
CY2020Q4 ocup Common Stock Capital Shares Available For Future Issuance
CommonStockCapitalSharesAvailableForFutureIssuance
446843
CY2020 ocup Number Of Small Molecule Product Candidates
NumberOfSmallMoleculeProductCandidates
2
CY2019 ocup Non Cash Interest On Convertible Notes Related Party
NonCashInterestOnConvertibleNotesRelatedParty
42000
CY2020 ocup Non Cash Interest On Convertible Notes Related Party
NonCashInterestOnConvertibleNotesRelatedParty
51000
CY2020 ocup Non Cash Discount Amortization On Convertible Notes Related Party
NonCashDiscountAmortizationOnConvertibleNotesRelatedParty
71000
CY2020Q4 ocup Number Of Milestones Accrued
NumberOfMilestonesAccrued
0
CY2020Q4 ocup Number Of Milestones Accrued
NumberOfMilestonesAccrued
0
CY2020Q4 ocup Number Of Directors Required To Complete Transition
NumberOfDirectorsRequiredToCompleteTransition
1
CY2020Q4 ocup Deferred Tax Assets Research And Development
DeferredTaxAssetsResearchAndDevelopment
275000
CY2019Q4 ocup Deferred Tax Assets Research And Development
DeferredTaxAssetsResearchAndDevelopment
0
CY2020 ocup Contingent Value Rights Payment Period
ContingentValueRightsPaymentPeriod
P15Y
CY2020Q4 ocup Percentage Of Cash Consideration Payment
PercentageOfCashConsiderationPayment
0.75
CY2020Q4 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
CY2020Q4 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
CY2020 ocup Contingent Value Rights Ip Term
ContingentValueRightsIPTerm
P10Y
CY2020 ocup Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Research And Development Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionResearchAndDevelopmentPercent
0.088
CY2019 ocup Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Research And Development Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionResearchAndDevelopmentPercent
0.000
CY2020 ocup Effective Income Tax Rate Reconciliation Warrants Percent
EffectiveIncomeTaxRateReconciliationWarrantsPercent
0.076
CY2019 ocup Effective Income Tax Rate Reconciliation Warrants Percent
EffectiveIncomeTaxRateReconciliationWarrantsPercent
0.000
CY2019 ocup Effective Income Tax Rate Reconciliation Pass Through Entity And Other Percent
EffectiveIncomeTaxRateReconciliationPassThroughEntityAndOtherPercent
0.001
CY2020 ocup Effective Income Tax Rate Reconciliation Pass Through Entity And Other Percent
EffectiveIncomeTaxRateReconciliationPassThroughEntityAndOtherPercent
0.000
CY2020 ocup Effective Income Tax Rate Reconciliation Convertible Notes Percent
EffectiveIncomeTaxRateReconciliationConvertibleNotesPercent
-0.033
CY2019 ocup Effective Income Tax Rate Reconciliation Convertible Notes Percent
EffectiveIncomeTaxRateReconciliationConvertibleNotesPercent
0.012
CY2020 ocup Operating Leases Monthly Base Rent
OperatingLeasesMonthlyBaseRent
3000
CY2019 ocup Non Cash Discount Amortization On Convertible Notes Related Party
NonCashDiscountAmortizationOnConvertibleNotesRelatedParty
101000
CY2020 ocup Financing Costs Reclassified From Operating Activities To Financing Activities
FinancingCostsReclassifiedFromOperatingActivitiesToFinancingActivities
4671000
CY2019 ocup Financing Costs Reclassified From Operating Activities To Financing Activities
FinancingCostsReclassifiedFromOperatingActivitiesToFinancingActivities
0
CY2020 ocup Number Of Directors Signed Waiver Agreements
NumberOfDirectorsSignedWaiverAgreements
6
CY2020Q4 ocup Business Combination Consideration Transferred Assets Incurred
BusinessCombinationConsiderationTransferredAssetsIncurred
68000
CY2020Q1 ocup Share Based Compensation Arrangements By Share Based Payment Award Grants In Period Straight Line Calculation Using Third Party Valuation Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardGrantsInPeriodStraightLineCalculationUsingThirdPartyValuationWeightedAverageGrantDateFairValue
1.74
CY2020Q2 ocup Share Based Compensation Arrangements By Share Based Payment Award Grants In Period Straight Line Calculation Using Third Party Valuation Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardGrantsInPeriodStraightLineCalculationUsingThirdPartyValuationWeightedAverageGrantDateFairValue
9.54
CY2020Q3 ocup Share Based Compensation Arrangements By Share Based Payment Award Grants In Period Third Party Valuation Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardGrantsInPeriodThirdPartyValuationWeightedAverageGrantDateFairValue
7.89
CY2020Q4 ocup Share Based Compensation Arrangements By Share Based Payment Award Grants In Period Third Party Valuation Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardGrantsInPeriodThirdPartyValuationWeightedAverageGrantDateFairValue
8.76

Files In Submission

Name View Source Status
0001140361-21-008099-index-headers.html Edgar Link pending
0001140361-21-008099-index.html Edgar Link pending
0001140361-21-008099.txt Edgar Link pending
0001140361-21-008099-xbrl.zip Edgar Link pending
brhc10021462_10k.htm Edgar Link pending
brhc10021462_ex10-38.htm Edgar Link pending
brhc10021462_ex10-41.htm Edgar Link pending
brhc10021462_ex10-42.htm Edgar Link pending
brhc10021462_ex10-43.htm Edgar Link pending
brhc10021462_ex21-1.htm Edgar Link pending
brhc10021462_ex23-1.htm Edgar Link pending
brhc10021462_ex31-1.htm Edgar Link pending
brhc10021462_ex31-2.htm Edgar Link pending
brhc10021462_ex32-1.htm Edgar Link pending
brhc10021462_ex4-11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image00001.jpg Edgar Link pending
image00002.jpg Edgar Link pending
image00003.jpg Edgar Link pending
image00004.jpg Edgar Link pending
image00005.jpg Edgar Link pending
image00006.jpg Edgar Link pending
image00008.jpg Edgar Link pending
image00009.jpg Edgar Link pending
image00010.jpg Edgar Link pending
image00011.jpg Edgar Link pending
image00013.jpg Edgar Link pending
image00014.jpg Edgar Link pending
image00015.jpg Edgar Link pending
image00017.jpg Edgar Link pending
image00018.jpg Edgar Link pending
image00023.jpg Edgar Link pending
image00034.jpg Edgar Link pending
ocup-20201231.xml Edgar Link completed
ocup-20201231.xsd Edgar Link pending
ocup-20201231_cal.xml Edgar Link unprocessable
ocup-20201231_def.xml Edgar Link unprocessable
ocup-20201231_lab.xml Edgar Link unprocessable
ocup-20201231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending